Minneapolis, MN5 Active Studies

Prostate Cancer Clinical Trials in Minneapolis, MN

Find 5 actively recruiting prostate cancer clinical trials in Minneapolis, MN. Connect with local research sites and explore new treatment options.

5
Active Trials
3
Sponsors
986
Enrolling

Recruiting Prostate Cancer Studies in Minneapolis

RecruitingMinneapolis, MNNCT04787744

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-...

464 participants
VA Office of Research and Development
View Study Details
RecruitingMinneapolis, MNNCT06014255

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12...

219 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details
RecruitingMinneapolis, MNNCT04363164

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to dete...

150 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details
RecruitingMinneapolis, MNNCT04038502

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant p...

100 participants
VA Office of Research and Development
View Study Details
RecruitingMinneapolis, MNNCT06228053

Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone....

53 participants
Syntrix Biosystems, Inc.
View Study Details

About Prostate Cancer Clinical Trials in Minneapolis

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 5 prostate cancer clinical trials recruiting participants in Minneapolis, MN. These studies are seeking a combined 986 participants. Research is being sponsored by VA Office of Research and Development, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Syntrix Biosystems, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in Minneapolis — FAQ

Are there prostate cancer clinical trials in Minneapolis?

Yes, there are 5 prostate cancer clinical trials currently recruiting in Minneapolis, MN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Minneapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you about next steps.

Are clinical trials in Minneapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Minneapolis studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 5 active trials in Minneapolis are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated March 2, 2026 from ClinicalTrials.gov